380 related articles for article (PubMed ID: 28187952)
1. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
Madan A; Ferguson M; Sheldon E; Segall N; Chu L; Toma A; Rheault P; Friel D; Soni J; Li P; Innis BL; Schuind A
Vaccine; 2017 Mar; 35(10):1431-1439. PubMed ID: 28187952
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.
Madan A; Ferguson M; Rheault P; Seiden D; Toma A; Friel D; Soni J; Li P; Innis BL; Schuind A
Vaccine; 2017 Apr; 35(15):1865-1872. PubMed ID: 28302407
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
Madan A; Segall N; Ferguson M; Frenette L; Kroll R; Friel D; Soni J; Li P; Innis BL; Schuind A
J Infect Dis; 2016 Dec; 214(11):1717-1727. PubMed ID: 27609809
[TBL] [Abstract][Full Text] [Related]
4. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
5. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
[TBL] [Abstract][Full Text] [Related]
6. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.
Mallett CP; Beaulieu E; Joly MH; Baras B; Lu X; Liu F; Levine MZ; Katz JM; Innis BL; Giannini SL
Vaccine; 2015 Jul; 33(32):3784-7. PubMed ID: 26100923
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.
Madan A; Collins H; Sheldon E; Frenette L; Chu L; Friel D; Drame M; Vaughn DW; Innis BL; Schuind A
Vaccine; 2017 Aug; 35(35 Pt B):4621-4628. PubMed ID: 28720281
[TBL] [Abstract][Full Text] [Related]
8. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
9. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
Langley JM; Frenette L; Jeanfreau R; Halperin SA; Kyle M; Chu L; McNeil S; Dramé M; Moris P; Fries L; Vaughn DW
Vaccine; 2015 Jan; 33(4):559-67. PubMed ID: 25448092
[TBL] [Abstract][Full Text] [Related]
11. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.
Kosalaraksa P; Jeanfreau R; Frenette L; Drame M; Madariaga M; Innis BL; Godeaux O; Izurieta P; Vaughn DW
J Infect Dis; 2015 Mar; 211(5):801-10. PubMed ID: 25293368
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
Chanthavanich P; Anderson E; Kerdpanich P; Bulitta M; Kanesa-Thasan N; Hohenboken M
Pediatr Infect Dis J; 2019 Jul; 38(7):757-764. PubMed ID: 31194712
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial.
Wu UI; Hsieh SM; Lee WS; Wang NC; Kung HC; Ou TY; Chen FL; Lin TY; Chen YC; Chang SC
Vaccine; 2017 Jul; 35(33):4099-4104. PubMed ID: 28668573
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.
Langley JM; Frenette L; Chu L; McNeil S; Halperin S; Li P; Vaughn D
BMC Infect Dis; 2012 Oct; 12():279. PubMed ID: 23110320
[TBL] [Abstract][Full Text] [Related]
19. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.
Carmona Martinez A; Salamanca de la Cueva I; Boutet P; Vanden Abeele C; Smolenov I; Devaster JM
Hum Vaccin Immunother; 2014; 10(7):1959-68. PubMed ID: 25424805
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
Langley JM; Scheifele DW; Quach C; Vanderkooi OG; Ward B; McNeil S; Dobson S; Kellner JD; Kuhn S; Kollman T; MacKinnon-Cameron D; Smith B; Li Y; Halperin SA
Vaccine; 2012 May; 30(23):3389-94. PubMed ID: 22469860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
